following a full submission:
voclosporin (Lupkynis®) is accepted for use within NHSScotland.
Indication under review: in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis.
Addition of voclosporin to mycophenolate mofetil significantly improved renal response rate in adults with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice354KB (PDF)
Medicine details
- Medicine name:
- voclosporin (Lupkynis)
- SMC ID:
- SMC2570
- Indication:
In combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).
- Pharmaceutical company
- Otsuka Pharmaceutical Europe
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 09 October 2023